Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial

Published:2022-10 Issue:10 Volume:9 Page:e745-e755
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Cramer Paula,Fürstenau Moritz,Robrecht Sandra,Giza Adam,Zhang Can,Fink Anna-Maria,Fischer Kirsten,Langerbeins Petra,Al-Sawaf Othman,Tausch Eugen,Schneider Christof,Schetelig Johannes,Dreger Peter,Böttcher Sebastian,Kreuzer Karl-Anton,Schilhabel Anke,Ritgen Matthias,Brüggemann Monika,Kneba Michael,Stilgenbauer Stephan,Eichhorst Barbara,Hallek Michael

Publisher

Elsevier BV

Subject

Hematology

Reference29 articles.

1. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial;Cramer;Lancet Oncol,2018

2. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia;de Rooij;Blood,2012

3. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo;Ponader;Blood,2012

4. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia;Cervantes-Gomez;Clin Cancer Res,2015

5. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia;Deng;Leukemia,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial;Blood;2024-07-18

2. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial;The Lancet Oncology;2024-06

3. Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review;Cancers;2024-03-26

4. Undetectable MRD on maintenance venetoclax, acalabrutinib, and obinutuzumab in the majority of R/R CLL participants;Medicom Conference Report ASH 2023;2024-02-07

5. Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer;Cancers;2023-03-14